NIH Grants Exclusive License for Powered Walking Aids Tech
Published Date: 2/27/2026
Notice
Summary
The National Institutes of Health plans to give Bionic Power Inc. an exclusive license to use new technology that helps people walk better, especially those with movement problems. This means Bionic Power can develop and sell these powered gait assistance systems worldwide. If you want to comment or apply for a license, you need to act by March 16, 2026.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Exclusive License for Gait Devices
The National Institutes of Health is contemplating granting Bionic Power Inc. an exclusive, royalty-bearing patent license to practice listed inventions for "Powered Gait Assistance Systems". The prospective exclusive license territory may be worldwide where patent rights exist and the field of use is limited to "the treatment of human movement disorders."
Royalty Requirement and Confidentiality
The prospective exclusive license will be royalty-bearing. License applications filed in response to this notice will be presumed to contain business confidential information and will be released only as required under the Freedom of Information Act; public comments (not part of license applications) will not be treated confidentially and may be made publicly available.
Deadline to Apply or Comment
If you want to apply for a license or comment on the contemplated exclusive license, written comments and/or license applications must be received by the NCI Technology Transfer Center on or before March 16, 2026. Complete license applications timely filed will be treated as objections to the grant.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2026-03992, Meeting of the Great Lakes St. Lawrence Seaway Development Corporation (GLS) Advisory Board
The Great Lakes St. Lawrence Seaway Development Corporation is hosting a virtual public meeting on March 26, 2026, to discuss important updates and plans for the Seaway. Anyone interested, especially businesses and communities relying on the Seaway, can join, speak, or submit materials by early March. This meeting helps shape future decisions that could impact shipping and regional economies.
Next: 2026-03997, Submission for Review: 3206-0237, Information and Instructions on Your Reconsideration Rights, RI 38-47
The Office of Personnel Management is asking for public feedback on the instructions about how federal employees can ask for a second look at decisions about their retirement, health benefits, or life insurance. This update keeps the process clear and easy to follow, with no new costs or deadlines added. If you’re a federal employee or retiree, now’s the time to share your thoughts before April 28, 2026!